Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTJWIQ)

Drug Name
LY2940680 Drug Info
Synonyms
LY2940680; 1258861-20-9; Taladegib; LY-2940680; UNII-QY8BWX1LJ5; 4-Fluoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl)piperidin-4-yl)-2-(trifluoromethyl)benzamide; QY8BWX1LJ5; Taladegib (LY2940680); LY 2940680; 4-fluoro-n-methyl-n-(1-(4-(1-methyl-1h-pyrazol-5-yl)-1-phthalazinyl)-4-piperidinyl)-2-(trifluoromethyl)benzamide; 4-Fluoro-N-Methyl-N-{1-[4-(1-Methyl-1h-Pyrazol-5-Yl)phthalazin-1-Yl]piperidin-4-Yl}-2-(Trifluoromethyl)benzamide; Taladegib [USAN:INN]
Cross-matching ID
PubChem CID
49848070
ChEBI ID
CHEMBL2142592
CAS Number
CAS 1258861-20-9
TTD Drug ID
D0W0SL
INTEDE Drug ID
DR1816

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ribosome biogenesis in eukaryotes 2.29 0.00e+0 52/108 (48.15%) RPP40;NXT2;NOP56;...
Proteasome 1.95 1.18e-2 44/46 (95.65%) PSMD11;PSMC3;ADRM1;...
Base excision repair 1.81 2.36e-2 29/33 (87.88%) POLE2;APEX1;FEN1;...
DNA replication 1.75 3.93e-2 34/36 (94.44%) POLE2;FEN1;MCM6;...
Oocyte meiosis 1.73 4.56e-2 90/129 (69.77%) CDC20;CUL1;CDK2;...
Natural killer cell mediated cytotoxicity -1.63 4.88e-2 99/131 (75.57%) FCER1G;RAC2;PIK3CA;...
Viral protein interaction with cytokine and cytokine re... -1.63 4.93e-2 84/100 (84%) CXCR3;CCR10;CCL16;...
Intestinal immune network for IgA production -1.66 4.05e-2 38/48 (79.17%) IL6;IL10;TNFRSF17;...
Steroid biosynthesis -1.66 4.03e-2 19/20 (95%) SOAT1;SC5D;CYP24A1;...
beta-Alanine metabolism -1.67 3.79e-2 25/30 (83.33%) ACOX1;ABAT;ALDH3A2;...
Th17 cell differentiation -1.68 3.62e-2 95/107 (88.79%) HIF1A;MAPK13;IL21R;...
Type I diabetes mellitus -1.69 3.43e-2 38/43 (88.37%) GZMB;CD86;FASLG;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.70 3.38e-2 79/89 (88.76%) MAP3K3;HIF1A;ALK;...
Asthma -1.70 3.54e-2 25/31 (80.65%) CD40LG;HLA-DPA1;HLA-DPB1;...
Tyrosine metabolism -1.71 3.38e-2 30/36 (83.33%) TYRP1;GOT1;ADH6;...
Glycolysis / Gluconeogenesis -1.72 3.15e-2 56/67 (83.58%) DLD;ADH6;ALDH3A2;...
B cell receptor signaling pathway -1.73 3.31e-2 71/81 (87.65%) LILRB1;CHUK;LILRB2;...
Systemic lupus erythematosus -1.73 3.18e-2 45/135 (33.33%) CD86;C1QA;CD40LG;...
Transcriptional misregulation in cancer -1.75 2.90e-2 158/192 (82.29%) JUP;IL6;PER2;...
Antigen processing and presentation -1.78 2.00e-2 60/78 (76.92%) NFYB;CREB1;CANX;...
Th1 and Th2 cell differentiation -1.80 1.60e-2 80/92 (86.96%) MAPK14;CD3G;MAPK3;...
Phenylalanine metabolism -1.81 1.55e-2 14/17 (82.35%) HPD;MIF;AOC3;...
Graft-versus-host disease -1.82 1.06e-2 32/42 (76.19%) KLRD1;HLA-A;IL6;...
Tuberculosis -1.84 1.14e-2 159/180 (88.33%) IFNGR1;AKT3;CEBPG;...
Aldosterone-regulated sodium reabsorption -1.86 1.14e-2 34/37 (91.89%) ATP1A1;NEDD4L;PIK3CA;...
IL-17 signaling pathway -1.90 6.87e-3 84/94 (89.36%) CXCL10;IL6;MMP9;...
Coronavirus disease -1.92 5.09e-3 215/232 (92.67%) RPL28;RPS29;MBL2;...
Leishmaniasis -1.93 5.72e-3 67/77 (87.01%) MAPK14;MAPK3;IL1A;...
Inflammatory bowel disease -1.95 3.27e-3 58/65 (89.23%) IL1A;SMAD2;TLR5;...
TNF signaling pathway -2.03 1.91e-3 103/112 (91.96%) PIK3CB;VEGFC;CXCL10;...
NF-kappa B signaling pathway -2.12 0.00e+0 90/104 (86.54%) CSNK2B;BCL2L1;EDA;...
Tryptophan metabolism -2.12 0.00e+0 35/42 (83.33%) ALDH3A2;ALDH9A1;CAT;...
Osteoclast differentiation -2.15 0.00e+0 117/127 (92.13%) SIRPB1;IFNGR1;STAT2;...
Staphylococcus aureus infection -2.19 0.00e+0 72/95 (75.79%) IL10;C2;PTAFR;...
Rheumatoid arthritis -2.71 0.00e+0 78/93 (83.87%) CSF2;CD86;IL18;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H